Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment (Q34625495)

3 August 2017

title

Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment (English)

1 reference

3 August 2017

0 references

1 reference

1 reference

Hoffmann D

1

1 reference

3 August 2017

Wildner O

series ordinal

2

1 reference

3 August 2017

publication date

4 May 2007

1 reference

3 August 2017

1 reference

3 August 2017

volume

14

1 reference

3 August 2017

issue

7

1 reference

3 August 2017

page(s)

627-639

1 reference

Current and future strategies for the treatment of malignant brain tumors.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

1 reference

7 January 2021

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Studies on the use of viruses in the treatment of carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

p53-dependent cell death/apoptosis is required for a productive adenovirus infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

The Ki-67 protein: from the known and the unknown

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

CD46 is a cellular receptor for group B adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

CD46 represents a target for adenoviral gene therapy of malignant glioma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Antibody-targeted cell fusion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Complementary adenoviral vectors for oncolysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Combination therapy with conditionally replicating adenovirus and replication defective adenovirus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

A simplified system for generating recombinant adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Enhanced cytotoxicity without internuclear spread of adenovirus upon cell fusion by measles virus glycoproteins.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Characterization of the effect of aphidicolin on adenovirus DNA replication: evidence in support of a protein primer model of initiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Effects of the Ad5 upstream E1 region and gene products on heterologous promoters

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Detection and subtyping of Herpes simplex virus in clinical samples by LightCycler PCR, enzyme immunoassay and cell culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Mechanistic analysis and comparison of viral fusogenic membrane proteins for their synergistic effects on chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701055

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7701055

1 reference

3 August 2017

1 reference